Ranitidine 75mg Tablets
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Ranitidine 75mg Tablets Or
Numark Indigestion Relief Tablets Or
Superdrug Heartburn & Indigestion Relief Tablets Or
Sainsbury’s Indigestion Relief Tablets Or
Numark Excess Acid Relief Tablets Or
Morrisons Indigestion Relief Tablets Or
Wilko Indigestion Relief Tablets Or
Boots Heartburn Relief 75 mg Tablets Or
Lloyds Pharmacy Indigestion Relief Tablets Or
Asda Indigestion Relief Tablets Or
Tesco Indigiestion Relief Tablets
Or
Gavilast 75mg Tablets
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 83.75 mg of Ranitidine Hydrochloride equivalent to 75 mg of Ranitidine.
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Film-coated tablet.
Light pink, round, biconvex, film-coated tablets printed with “75” in black edible ink on one side.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Symptomatic relief of heartburn, indigestion, acid indigestion and hyperacidity.
4.2 Posology and method of administration
For Pharmacy (P) Packs Posology
Adults (including the elderly) and adolescents of 16 years of age and older.
One Ranitidine tablet 75mg should be taken when symptoms occur, day or night. Do not take more than two tablets in 24 hours.
Patients will be instructed not to take the tablets for more than 2 weeks continuously. They must consult their doctor if symptoms deteriorate or persist after 2 weeks treatment.
Children under 16 years.
The tablets are not recommended for children under 16 years of age.
For General Sales (GSL) Packs Posology
Adults (including the elderly) and children 16 years of age and older:
Swallow one Ranitidine 75mg Tablet whole, with a drink of water, as soon as you have symptoms. If symptoms persist for more than one hour or return, take another tablet. Do not take more than two tablets in 24 hours.
Do not take the tablets for more than 6 days without the advice of a pharmacist or doctor.
Patients will be instructed not to take the tablets for more than 6 weeks continuously. They must consult their doctor or pharmacist if symptoms deteriorate or persist after 6 days treatment. They should not purchase a second pack of tablets without the advice of a pharmacist or doctor.
Paediatric population
The tablets are not recommended for children under 16 years of age.
4.3 Contraindications
Ranitidine is contraindicated for people known to be hypersensitive to the active substance or to any of the excipients listed in section 6.1.
Ranitidine tablets or Histac tablets should not be given to children under 16 years of age.
4.4 Special warnings and precautions for use
Treatment with a histamine (H2) antagonist such as Rantidine 75mg Tablets may mask symptoms associated with carcinoma of the stomach and may therefore delay diagnosis of the condition.
Ranitidine is excreted via the kidney and so plasma levels of the drug are
increased in patients with renal impairment (creatinine clearance less than 50 ml/min). Ranitidine 75mg Tablets is not suitable for these patients without medical supervision.
People taking non-steroidal anti-inflammatory drugs, especially those with a history of peptic ulcer and the elderly, should not self-medicate with Ranitidine 75mg Tablets but seek their doctor's advice before use.
People with a history of porphyria should avoid use of the product.
Consumers will be advised not to purchase a second pack of tablets without the advice of a pharmacist of doctor.
The product is not indicated in the following people without seeking their doctor's advice:
• Patients with renal impairment (creatinine clearance less than 50ml/min) and/or hepatic impairment.
• Patients under regular medical supervision for other reasons.
• Patients taking medications either physician prescribed or self prescribed.
• Those with difficulty swallowing, persistent stomach pain or unintended weight loss in association with symptoms of indigestion.
• Those who are middle-aged or elderly with new or recently changed symptoms of indigestion.
In patients such as the elderly, persons with chronic lung disease, diabetes or the immunocompromised, there may be an increased risk of developing community acquired pneumonia.
A large epidemiological study showed an increased risk of developing community acquired pneumonia in current users of ranitidine alone versus those who had stopped treatment, with an observed adjusted relative risk increase of 1,82 (95% CI 1,26-2,64).
4.5 Interactions with other medicinal products and other forms of interaction
Ranitidine has the potential to affect the absorption, metabolism or renal excretion of other drugs. The altered pharmacokinetics may necessitate dosage adjustment of the affected drug or discontinuation of treatment.
Interactions occur by several mechanisms including:
1) Inhibition of cytochrome P450-linked mixed function oxygenese system:
Ranitidine at usual therapeutic doses does not potentiate the actions of drugs which are inactivated by this enzyme such as diazepam, lidocaine, phenytoin, propranolol and theophylline.
There have been reports of altered prothrombin time with coumarin anticoagulants (e.g. warfarin). Due to the narrow therapeutic index, close monitoring of increased or decreased prothrombin time is recommended during concurrent treatment with ranitidine.
2) Alteration of gastric pH:
The bioavailability of certain drugs may be affected. This can result in either an increase in absorption or a decrease in absorption.
4.6 Fertility, pregnancy and lactation
Pregnancy
Ranitidine 75mg crosses the placenta but therapeutic doses administered to obstetric patients in labour or undergoing caesarean section have been without any adverse effect on labour, delivery or subsequent neonatal progress. Like other over the counter drugs, Ranitidine 75mg Tablets should not be taken during pregnancy without consulting a doctor or pharmacist.
Breastfeeding
Ranitidine is also excreted in human breast milk and women who are breastfeeding will be advised to speak to their doctor before taking Ranitidine 75mg Tablets.
4.7 Effects on the ability to drive and use machines
No known effect.
4.8 Undesirable Effects
The following convention has been utilised for the classification of undesirable effects: very common (>1/10), common (>1/100, <1/10), uncommon (>1/1000, <1/100), rare (>1/10,000, <1/1000), very rare (1/10,000).
Adverse event frequencies have been estimated from spontaneous reports from post-marketing data.
Blood & Lymphatic System Disorders
Very Rare: Blood count changes (leucopenia, thrombocytopenia). These are usually reversible. Agranulocytosis or pancytopenia, sometimes with marrow hypoplasia or marrow aplasia.
Immune System Disorders
Rare: Hypersensitivity reactions (urticaria, angioneurotic oedema, fever, bronchospasm, hypotension and chest pain).
Very Rare: Anaphylactic shock
These events have been reported after a single dose.
Psychiatric Disorders
Very Rare: Reversible mental confusion, depression and hallucinations.
These have been reported predominantly in severely ill and elderly patients. Nervous System Disorders
Very Rare: Headache (sometimes severe), dizziness and reversible involuntary movement disorders.
Eye Disorders
Very Rare: Reversible blurred vision.
There have been reports of blurred vision, which is suggestive of a change of accommodation.
Cardiac Disorders
Very Rare: As with other H2 receptor antagonists bradycardia and A-V Block.
Vascular Disorders
Very Rare: Vasculitis.
Gastrointestinal Disorders
Very Rare: Acute pancreatitis. Diarrhoea.
Uncommon: Abdominal pain, constipation, nausea. (these symtoms mostly improved during continued treatment).
Hepatobiliary Disorders
Rare: Transient and reversible changes in liver function tests.
Very Rare: Hepatitis (hepatocellular, hepatocanalicular or mixed) with or without jaundice, these were usually reversible.
Skin and Subcutaneous Tissue Disorders
Rare: Skin Rash.
Very Rare: Erythema multiforme, alopecia.
Musculoskeletal and Connective Tissue Disorders
Very Rare: Musculoskeletal symptoms such as arthralgia and myalgia.
Renal and Urinary Disorders Very rare: Acute interstitial nephritis.
Rare: Elevation of plasma creatinine (usually slight; normalised during continued treatment)
Reproductive System and Breast Disorders
Very Rare: Reversible impotence. Breast symptoms and breast conditions (such as gynaecomastia and galactorrhea)
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, website www.mhra.gov.uk/yellowcard.
4.9 Overdose
Ranitidine is very specific in action and accordingly no particular problems are expected following overdosage with the drug. Symptomatic and supportive therapy should be given as appropriate. If need be, the drug may be removed from the plasma by haemodialysis.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
ATC Code: A02B A (H2-receptor antagonist)
Mode of action
Ranitidine is a specific, rapidly acting histamine H2 - antagonist. It inhibits basal and stimulated secretion of gastric acid, reducing both the volume and the acid and pepsin content of the secretion . Ranitidine has a long duration of action and a single 75 mg dose supresses gastric acid secretion for up to 12 hours.
Clinical studies have shown that Ranitidine 75 mg can relieve the symptoms of excess acid production for up to twelve hours.
5.2 Pharmacokinetic properties
Absorption
Following oral administration of 150 mg ranitidine, maximum plasma concentrations (300 to 550 ng/mL) occurred after 1-3 hours. Two distinct peaks or a plateau in the absorption phase result from reabsorption of drug excreted into the intestine. The absolute bioavailability of ranitidine is 5060%, and plasma concentrations increase proportionally with increasing dose up to 300 mg.
Absorption is not significantly impaired by food or antacids.
Distribution
Ranitidine is not extensively bound to plasma proteins (15%), but exhibits a large volume of distribution ranging from 96 to 142L.
Metabolism
Ranitidine is not extensively metabolised. The fraction of the dose recovered as metabolites includes 6% of the dose in urine as the N-Oxide, 2% as the S-Oxide, 2% as desmethyl ranitidine and 1-2% as the furoic acid analogue.
Elimination
Plasma concentrations decline bi-exponentially, with a terminal half-life of 2-3 hours. The major route of elimination is renal. After IV administration of 150 mg 3H-ranitidine, 98% of the dose was recovered, including 5% in the faeces and 93% in the urine, of which 70% was unchanged parent drug. After oral administration of 150 mg 3H-ranitidine, 96% of the dose was recovered, 26% in the faeces and 70% in urine of which 35% was unchanged parent drug. Less than 3% of the dose is excreted in bile. Renal clearance is approximately 500mL/min, which exceeds glomerular filtration indicating net renal tubular secretion.
Special Patient Populations
• Patients over 50 years of age
In patients over 50 years of age, half-life is prolonged (3-4 h) and clearance is reduced, consistent with the age-related decline of renal function. However, systemic exposure and accumulation are 50% higher. This difference exceeds the effect of declining renal function, and indicates increased bioavailability in older patients.
5.3 Preclinical safety data
Extensive studies have been carried out in animals. The pharmacology of ranitidine hydrochloride shows it to be a surmountable H2 receptor antagonist which produces an inhibition of gastro acid secretion. Extensive toxicological investigators have been conducted which predicted a very safe profile for clinical use. This safety has since been confirmed by extensive use in patients for many years.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Microcrystalline cellulose Croscarmellose sodium Colloidal anhydrous silica Magnesium stearate Talc
Film coating material:
Castor oil
Opadry OY-S-54902 Pink containing
Hypromellose
Talc
Titanium dioxide (E171)
Red ferric oxide (E172)
Printing ink:
Opacode S-1-17823 Black containing Shellac
Isopropyl alcohol Iron oxide black (E172)
N-Butyl alcohol Propylene glycol Ammonium Hydroxide 28%
6.2 Incompatibilities
Not Applicable.
6.3
Shelf life
3 years.
6.4 Special precautions for storage
Keep the blister in the outer carton in order to protect from light. Do not store above 25°C.
6.5 Nature and contents of container
Ranitidine Tablets or Histac Tablets are packed in cold-form blister sheets (structure from outer to inner side: oriented polyamide/aluminium foil/hard PVC film with a backing of aluminium foil coated with heat seal lacquer), each containing 6 or 7 or 10 tablets.
Packs of 6 or 10 or 12 or 20 or 24 or 28 tablets.
6.6 Special precautions for disposal
No special requirements.
7. MARKETING AUTHORISATION HOLDER
Ranbaxy (UK) Ltd.
Buildind 4, Chiswick Park 566 Chiswick High Road London, W4 5YE U.K.
8. MARKETING AUTHORISATION NUMBER
14894/0041
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
21 November 2000
10 DATE OF REVISION OF THE TEXT
29/06/2016